EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 121 filers reported holding EPIZYME INC in Q1 2022. The put-call ratio across all filers is 4.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $13,000 | +30.0% | 8,900 | 0.0% | 0.00% | – |
| Q1 2022 | $10,000 | -95.3% | 8,900 | -89.6% | 0.00% | – |
| Q4 2021 | $213,000 | +373.3% | 85,939 | +865.6% | 0.00% | – |
| Q3 2021 | $45,000 | -92.6% | 8,900 | -87.9% | 0.00% | -100.0% |
| Q2 2021 | $608,000 | -54.7% | 73,343 | -52.4% | 0.00% | -50.0% |
| Q1 2021 | $1,341,000 | +65.1% | 154,139 | +106.3% | 0.00% | 0.0% |
| Q4 2020 | $812,000 | -15.0% | 74,720 | -6.7% | 0.00% | 0.0% |
| Q3 2020 | $955,000 | -25.7% | 80,095 | 0.0% | 0.00% | -33.3% |
| Q2 2020 | $1,285,000 | +3.3% | 80,095 | -0.2% | 0.00% | 0.0% |
| Q1 2020 | $1,244,000 | +13.5% | 80,216 | +79.9% | 0.00% | +50.0% |
| Q4 2019 | $1,096,000 | +2183.3% | 44,592 | +471.7% | 0.00% | – |
| Q4 2018 | $48,000 | -12.7% | 7,800 | +50.0% | 0.00% | – |
| Q3 2018 | $55,000 | -88.8% | 5,200 | -86.2% | 0.00% | -100.0% |
| Q4 2017 | $489,000 | -31.7% | 37,578 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $716,000 | +19.9% | 37,578 | -5.1% | 0.00% | 0.0% |
| Q2 2017 | $597,000 | -23.3% | 39,590 | -12.7% | 0.00% | 0.0% |
| Q1 2017 | $778,000 | +121.7% | 45,343 | +59.6% | 0.00% | 0.0% |
| Q4 2016 | $351,000 | – | 28,419 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |